Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Hydroxyurea for Malnutrition in Sickle Cell Disease
NCT03634488Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Aug 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of hydroxyurea in sickle cell anemia (SCA) (3 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Enrollment Rate at the End of the 6-month Recruitment Period, Retention Over 12-week Period and 8 more. Started Aug 2021; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT03634488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634488.